“Dramatic changes in the financial markets have largely eliminated sell side research coverage for all but the largest and most actively traded stocks. This leaves some of the most promising equity investment
opportunities inaccessible to most investors. Enter OMP Research.”
OneMedPlace announces their first issue of OMP Research, following promising small public healthcare and life science companies that they think are significantly undervalued.
Companies profiled in this issue:
DataTrak – [DATA.PK] Clinical trials software management
Novadaq – [NDQ.TO] Surgical optics and diagnostics
PLC Medical – [PLCSF.OB] Renal care
Vasomedical – [VASO.PK] New treatments for cardiovascular diseases
Wound Management – [WNDM.PK] Wound healing technologies
Dowload the report: 2011_ResearchReportNovember
